We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 21, 2020

Axalimogene Filolisbac for Platinum-Refractory Cervical Carcinoma

Gynecologic Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Gynecologic Oncology
Phase II Study of Axalimogene Filolisbac (ADXS-HPV) for Platinum-Refractory Cervical Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
Gynecol. Oncol 2020 Jul 05;[EPub Ahead of Print], WK Huh, WE Brady, PM Fracasso, DS Dizon, MA Powell, BJ Monk, CA Leath, LM Landrum, EJ Tanner, EK Crane, S Ueda, MT McHale, C Aghajanian

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading